版本:
中国

BRIEF-Compugen ltd selects of com902 as lead clinical antibody candidate for immuno-oncology program

March 28 Compugen Ltd:

* Compugen Ltd - selection of com902 as lead clinical antibody candidate for cgen-15137/tigit t cell checkpoint inhibitor program in immuno-oncology Source text:(bit.ly/2oceUEM) Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐